ESMC — what changed in the latest 10-Q
A section-by-section comparison of ESMC's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-15 vs the prior 10-Q · 2026-02-17
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +10 | −10 | ~30 | 12 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~3 | 1 |
| Legal proceedings | Text added/removed | 0 | 0 | ~1 | 0 |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Risk factors
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-15
Certain statements contained in, or incorporated by reference in, this Quarterly Report on Form 10-Q are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which provide current expectations or forecasts of future events. S…
to materialize as anticipated, including risks related to inflation and tariffs, the ability to continue as a going concern including the ability to raise capital, manage operations and pursue business partnerships and cost-cutting measures, and the other risks described in the Company's Form 10-K f…
•Consolidated net revenue decreased approximately $601,000 or 6.3%, to $8,875,000 during the nine months ended March 31, 2026 as compared to the same period of last fiscal year. The decrease in net revenue is mainly attributed to a decrease of $310,000 in sales of Sonomed products, a decrease of $30…
Consolidated net revenue decreased approximately $865,000 or 24.9%, to $2,609,000 during the three months ended March 31, 2026 as compared to the same period of last fiscal year. The decrease in net revenue is mainly attributed to a decrease of $701,000 in sales of Sonomed products, a decrease of $9…
Consolidated net revenue decreased approximately $601,000 or 6.3%, to $8,875,000 during the nine months ended March 31, 2026 as compared to the same period of last fiscal year. The decrease in net revenue is mainly attributed to a decrease of $310,000 in sales of Sonomed products, a decrease of $305…
Text removed vs the prior filing · source: 10-Q · 2026-02-17
Certain statements contained in, or incorporated by reference in, this Quarterly Report on Form 10-Q are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which provide current expectations or forecasts of future events. S…
discontinued operations, research and development, product development, the introduction of new products, the potential markets and uses for the Company's products, the Company's ability to increase its sales campaign effectively, the Company's regulatory filings with the FDA, acquisitions, disposit…
•Consolidated net revenue increased approximately $265,000 or 4.4%, to $6,267,000 during the six months ended December 31, 2025 as compared to the same period of last fiscal year. The increase in net revenue is mainly attributed to an increase of $455,000 in sales of Sonomed products, offset by a de…
Consolidated net revenue increased approximately $370,000 or 11.5%, to $3,591,000 during the three months ended December 31, 2025 as compared to the same period of last fiscal year. The increase in net revenue is mainly attributed to an increase of $583,000 in sales of Sonomed products, offset by a …
Consolidated net revenue increased approximately $265,000 or 4.4%, to $6,267,000 during the six months ended December 31, 2025 as compared to the same period of last fiscal year. The increase in net revenue is mainly attributed to an increase of $455,000 in sales of Sonomed products, offset by a dec…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice